CorMedix Inc
$ 7.44
-0.93%
07 Aug - close price
- Market Cap 583,682,000 USD
- Current Price $ 7.44
- High / Low $ 7.58 / 7.39
- Stock P/E 3.46
- Book Value 5.58
- EPS 2.15
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.26 %
- ROE 0.66 %
- 52 Week High 14.96
- 52 Week Low 6.12
About
CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. The company is headquartered in Berkeley Heights, New Jersey.
Analyst Target Price
$15.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-03-05 | 2025-11-12 | 2025-08-07 | 2025-05-06 | 2025-03-25 | 2024-10-30 | 2024-08-14 | 2024-05-09 | 2024-03-12 | 2023-11-14 | 2023-08-08 |
| Reported EPS | 0.35 | 0.1601 | 1.41 | 0.28 | 0.3 | 0.22 | -0.05 | -0.25 | -0.25 | -0.26 | -0.17 | -0.25 |
| Estimated EPS | 0.33 | 0.7357 | 0.63 | 0.2 | 0.25 | 0.14 | -0.1 | -0.25 | -0.28 | -0.2 | -0.21 | -0.24 |
| Surprise | 0.02 | -0.5756 | 0.78 | 0.08 | 0.05 | 0.08 | 0.05 | 0 | 0.03 | -0.06 | 0.04 | -0.01 |
| Surprise Percentage | 6.0606% | -78.2384% | 123.8095% | 40% | 20% | 57.1429% | 50% | 0% | 10.7143% | -30% | 19.0476% | -4.1667% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.26 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRMD
2026-08-08 05:09:54
This article announces that CorMedix (CRMD) is scheduled to report its financial results pre-market on August 13. Investors will be keen to see if the company met expectations, with analysts forecasting a loss of $0.06 per share and revenues of $0.46 million. The report will likely influence the stock's performance following a recent 16.5% decline.
2026-08-08 01:09:54
This article reports on CorMedix Inc.'s (CRMD) filing of a Form 8K on August 7. The filing is a standard SEC document used by companies to announce unscheduled material events or corporate changes that shareholders should know about. The brief piece indicates that Investing.com is the source of this financial markets news.
2026-08-08 01:09:54
CorMedix has received preliminary court approval for a proposed derivative settlement which includes the implementation of corporate governance reforms for at least 3.5 years. A final hearing is scheduled for September 23, 2026. The settlement does not provide a monetary fund for stockholders, and plaintiffs' counsel will seek up to $3.9 million in attorneys' fees, which defendants reserve the right to oppose.
2026-08-07 09:40:59
Pacer Advisors Inc. significantly increased its stake in CorMedix Inc. by 128.7% in the first quarter, acquiring an additional 326,724 shares to hold a total of 580,620 shares valued at $3.94 million. Institutional investors now collectively own 34.18% of CRMD, while analysts maintain a "Moderate Buy" consensus rating with an average price target of $14.86. The company recently reported strong quarterly earnings, beating EPS estimates and showing a substantial year-over-year revenue increase of 226.1%.
2026-08-07 08:40:59
Empowered Funds LLC significantly increased its stake in CorMedix Inc (NASDAQ:CRMD) by 102.1% in the first quarter, now owning 266,637 shares valued at $1.81 million. Institutional investors collectively hold 34.18% of Cor
2026-08-05 17:50:00
This article from Stock Traders Daily analyzes Cormedix Inc. (NASDAQ: CRMD), highlighting strong near-term sentiment that could challenge persistent mid and long-term weakness. It identifies an exceptional 89.0:1 risk-reward setup, targeting a 27.1% gain versus a 0.3% risk. The analysis includes three AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging) and a multi-timeframe signal analysis for CRMD.
